Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CXD101 Given Orally (Twice Daily Dosing for 5 Consecutive Days in a 21-day Period) in Patients With Advanced Malignancies Expressing the Biomarker HR23B

Trial Profile

Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CXD101 Given Orally (Twice Daily Dosing for 5 Consecutive Days in a 21-day Period) in Patients With Advanced Malignancies Expressing the Biomarker HR23B

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs CXD 101 (Primary)
  • Indications Lymphoma; Myeloma; Solid tumours
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 06 Dec 2016 Preliminary results (n=36) assessing safety and activity in relapsed or refractory Hodgkin and Non-Hodgkin Lymphoma patients, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 20 Oct 2016 Last checked against ClinicalTrials.gov record.
    • 16 Oct 2016 Planned End Date changed from 1 Apr 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top